Heart Failure with Reduced Ejection Fraction

Detailed Overview

HFrEF is the classic form of heart failure, heavily driven by ischemic heart disease or cardiomyopathies. The hallmark is an enlarged, dilated left ventricle with poor contractility. The clinical significance of HFrEF lies in its high morbidity, frequent hospitalizations, and significant mortality rate. The management paradigm has shifted from simply treating symptoms with diuretics to utilizing 'guideline-directed medical therapy' (GDMT) that fundamentally blocks the maladaptive neurohormonal pathways (RAAS and SNS), thereby reversing cardiac remodeling and prolonging survival.

Epidemiology & Demographics

Affects approximately 3 million adults in the US (roughly half of all HF cases). Incidence increases steeply with age. Higher prevalence in men and African Americans. The 5-year mortality rate remains approximately 50% despite medical advances.

Etiological Mechanism

The most common etiology is Coronary Artery Disease (CAD) leading to myocardial infarction and subsequent ischemic cardiomyopathy. Non-ischemic causes include viral myocarditis, cardiotoxins (anthracyclines like doxorubicin, alcohol, cocaine), genetic mutations (titin mutations in dilated cardiomyopathy), and long-standing uncontrolled hypertension.

Primary Causes

Myocardial infarction, viral myocarditis (Coxsackie B, Parvovirus), Doxorubicin toxicity, Chagas disease, idiopathic dilated cardiomyopathy.

• Prior Myocardial Infarction: Loss of viable myocardium creates a scar, leaving the remaining tissue to hyper-function and eventually fail.
• Hypertension: Increases afterload, initially causing hypertrophy but eventually leading to ventricular dilation and systolic failure.

An initial insult (e.g., myocardial infarction) reduces cardiac output. This triggers baroreceptors to activate the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS) to maintain blood pressure and organ perfusion. Norepinephrine increases heart rate and contractility, while Angiotensin II causes vasoconstriction and stimulates Aldosterone, leading to sodium and water retention. While acutely beneficial, chronic activation of these pathways is profoundly cardiotoxic. They promote apoptosis, interstitial fibrosis, and myocyte hypertrophy, driving pathological left ventricular remodeling (spherical dilation of the LV) and further worsening ejection fraction.

Characteristic Clinical Presentation

• Dyspnea on Exertion: Shortness of breath during physical activity due to elevated pulmonary capillary wedge pressure.
• Orthopnea: Shortness of breath when lying flat, caused by redistribution of blood from splanchnic and lower extremity beds to the lungs, requiring the patient to sleep propped up on pillows.
• Paroxysmal Nocturnal Dyspnea (PND): Waking up gasping for air 1-2 hours after falling asleep.

Physical Examination Signs

• S3 Gallop: An extra heart sound in early diastole caused by rapid ventricular filling into a dilated, non-compliant ventricle.
• Jugular Venous Distension (JVD): Engorgement of the jugular vein > 8 cm above the right atrium, indicating elevated right-sided filling pressures.
• Laterally displaced Point of Maximal Impulse (PMI) due to LV dilation.

• Arrhythmias: High risk of ventricular tachycardia or fibrillation due to myocardial scarring, leading to sudden cardiac death.
• Cardiorenal Syndrome: Worsening renal function driven by poor cardiac output (forward failure) and central venous congestion (backward failure).

Diagnostic Criteria & Guidelines

Clinical signs/symptoms of heart failure PLUS an echocardiogram demonstrating a Left Ventricular Ejection Fraction (LVEF) ≤ 40%. Elevated natriuretic peptides support the diagnosis.

Differential Diagnosis

• COPD Exacerbation
• Pulmonary Embolism
• Heart Failure with Preserved Ejection Fraction (HFpEF)

Laboratory Tests & Biomarkers

• N-terminal pro-BNP (NT-proBNP): > 450 pg/mL in patients < 50 yrs, or > 900 pg/mL in patients 50-75 yrs (highly sensitive for elevated filling pressures).
• Serum Sodium: Hyponatremia (< 135 mEq/L) in advanced stages due to non-osmotic vasopressin release.

Imaging Modalities & Findings

• Transthoracic Echocardiogram (TTE):
• Chest X-Ray:

• NYHA Class II
  Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue or dyspnea.
• NYHA Class IV
  Unable to carry on any physical activity without discomfort. Symptoms of heart failure are present even at rest.

Second-Line & Adjunctive Therapy

Ivabradine 5 mg BID for patients in sinus rhythm with HR ≥ 70 bpm on max tolerated beta-blocker. Hydralazine/Isosorbide Dinitrate specifically for self-identified African American patients with ongoing NYHA Class III-IV symptoms despite quadruple therapy.

Surgical & Procedural Management

Implantable Cardioverter-Defibrillator (ICD) for primary prevention of sudden cardiac death if LVEF ≤ 35% and life expectancy > 1 year. Cardiac Resynchronization Therapy (CRT-D) if QRS duration ≥ 150 ms with LBBB pattern. Advanced options: Left Ventricular Assist Device (LVAD) or Orthotopic Heart Transplantation.

Recommended Lifestyle Changes

• Strict daily weight monitoring (call provider for weight gain > 2-3 lbs in 24 hours or 5 lbs in a week).
• Sodium restriction (< 2000 mg/day) and fluid restriction (1.5-2 Liters/day) in advanced stages.

Patient Counseling & Advice

Emphasize that GDMT medications (Beta-blockers, ARNIs, etc.) are meant to make the heart stronger and prolong life over months/years, not necessarily to make them feel instantly better today. Compliance is paramount. Warn against using NSAIDs which worsen fluid retention.

Follow-Up & Monitoring Schedule

Recheck basic metabolic panel (Creatinine, Potassium) 1-2 weeks after initiating or titrating RAAS inhibitors (ARNI, Spironolactone). Echocardiogram every 3-6 months after optimizing medical therapy to check for EF recovery.

Preventive Strategies

Aggressive treatment of hypertension and hyperlipidemia; prompt reperfusion therapy in acute myocardial infarction to save myocardium.

Highly dependent on GDMT adherence and baseline EF. 5-year survival is roughly 50%. However, optimal quadruple therapy significantly reduces mortality and can result in 'Heart failure with improved EF' (LVEF rising > 40%).